The North America Smart Insulin Pens Market would witness market growth of 9.8% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 234.2 thousand units, showcasing a growth of 9.2% (2019-2022).
Diabetes is a long-term medical condition marked by high blood glucose levels. In order to keep levels of blood glucose under control, regular insulin administration is frequently necessary. Therefore, the development and adoption of these pens have become instrumental in enhancing the quality of life for individuals with diabetes, improving treatment outcomes, and streamlining the management of this complex condition.
The requirement for the pens can be traced back to the inherent challenges faced by both patients and healthcare providers in managing diabetes effectively. Traditional insulin delivery methods, such as syringes and vials, are associated with several limitations, including imprecise dosing, difficulties keeping accurate records, and the potential for dosage errors. Patients often struggle with keeping detailed logs of their insulin injections, leading to potential inaccuracies and missed doses. Healthcare providers, on the other hand, face challenges in tracking their patients' progress accurately and may struggle to make informed decisions regarding insulin therapy adjustments.
The Canadian Government committed to investing $35 million in diabetes research, prevention, and surveillance in 2021. Of that amount, $25 million was allocated to create a national framework for diabetes and diabetes research. This includes reaffirming support for the Partnership to Defeat Diabetes between the Canadian Institutes of Health Research (CIHR) and the Juvenile Diabetes Research Foundation (JDRF) by contributing up to $15 million for type 1 diabetes research, with contributions matched by JDRF Canada and its donors. These developments have resulted in an increasing demand for technologically advanced diabetes management devices. Thus, such factors collectively contribute to the growing popularity of these pens as a preferred choice for diabetes management in regional countries.
The US market dominated the North America Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $52,584.4 Thousands by 2030. The Canada market is experiencing a CAGR of 12.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 11.3% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
Diabetes is a long-term medical condition marked by high blood glucose levels. In order to keep levels of blood glucose under control, regular insulin administration is frequently necessary. Therefore, the development and adoption of these pens have become instrumental in enhancing the quality of life for individuals with diabetes, improving treatment outcomes, and streamlining the management of this complex condition.
The requirement for the pens can be traced back to the inherent challenges faced by both patients and healthcare providers in managing diabetes effectively. Traditional insulin delivery methods, such as syringes and vials, are associated with several limitations, including imprecise dosing, difficulties keeping accurate records, and the potential for dosage errors. Patients often struggle with keeping detailed logs of their insulin injections, leading to potential inaccuracies and missed doses. Healthcare providers, on the other hand, face challenges in tracking their patients' progress accurately and may struggle to make informed decisions regarding insulin therapy adjustments.
The Canadian Government committed to investing $35 million in diabetes research, prevention, and surveillance in 2021. Of that amount, $25 million was allocated to create a national framework for diabetes and diabetes research. This includes reaffirming support for the Partnership to Defeat Diabetes between the Canadian Institutes of Health Research (CIHR) and the Juvenile Diabetes Research Foundation (JDRF) by contributing up to $15 million for type 1 diabetes research, with contributions matched by JDRF Canada and its donors. These developments have resulted in an increasing demand for technologically advanced diabetes management devices. Thus, such factors collectively contribute to the growing popularity of these pens as a preferred choice for diabetes management in regional countries.
The US market dominated the North America Smart Insulin Pens Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $52,584.4 Thousands by 2030. The Canada market is experiencing a CAGR of 12.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 11.3% during (2023 - 2030).
Based on Usability, the market is segmented into Prefilled, and Reusable. Based on Product, the market is segmented into First Generation Pens, and Second Generation Pens (USB Connected, Bluetooth-Enabled). Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG.
Scope of the Study
Market Segments Covered in the Report:
By Usability (Volume, Thousand Units, Revenue, USD Million, 2019-30)- Prefilled
- Reusable
- First Generation Pens
- Second Generation Pens
- USB Connected
- Bluetooth-Enabled
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F.Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. North America Smart Insulin Pens Market, By Usability
Chapter 6. North America Smart Insulin Pens Market, By Product
Chapter 7. North America Smart Insulin Pens Market, By End User
Chapter 8. North America Smart Insulin Pens Market, By Country
Chapter 9. Company Profiles
Companies Mentioned
- Medtronic PLC
- Eli Lilly And Company
- Novo Nordisk A/S
- F. Hoffmann-La Roche Ltd
- Emperra GmbH
- Jiangsu Delfu Medical Device Co.,Ltd
- Abbott Laboratories
- Ypsomed AG
Methodology
LOADING...
